Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | WRN | Q14191 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027921 | 1.00 | ALDH1A1 (0.30) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL1028081 | 0.91 | USP2 (0.34) | ALDH1A1 | |
| SCHEMBL1025836 | 0.91 | USP2 (0.34) | ALDH1A1 | |
| SCHEMBL1026071 | 0.86 | ALDH1A1 (0.32) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL1027339 | 0.86 | ALDH1A1 (0.32) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL1026590 | 0.83 | KCNA5 (0.33) | ALDH1A1BLMLIPE | |
| SCHEMBL1028734 | 0.81 | MGLL (0.30) | — | |
| SCHEMBL1026784 | 0.81 | MGLL (0.30) | — | |
| SCHEMBL1027067 | 0.79 | CTSV (0.39) | — | |
| SCHEMBL1029006 | 0.79 | CTSV (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479669-B1 | Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography | TOSOH CORP (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7645889-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7381742-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-06-14 | — | — | US | disclosed |
| US-7186750-B2 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1479669-A1 | Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography | Tosoh Corporation (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | CYBA, COASY, MEP1B | ALDH1A1 2920/4885CYP1A2 937/4885HPGD 359/4885 |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, CYBA | ALDH1A1 2838/4885CYP1A2 1239/4885HPGD 892/4885 |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, ACMSD | ALDH1A1 3302/4885CYP1A2 1283/4885HPGD 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.